Paclitaxel

目录号:S1150 别名: NSC 125973

Paclitaxel Chemical Structure

Molecular Weight(MW): 853.91

Paclitaxel是一种microtubule聚合物稳定剂,在人内皮细胞中IC50为0.1 pM。

规格 价格 库存 购买数量  
RMB 749.07 现货
RMB 571.49 现货
RMB 2235.46 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的5个实验数据:

  • (F) Kaplan-Meier curves are shown for all groups described: no hydrogel, a hydrogel loaded with paclitaxel, or a hydrogel loaded with doxorubicin. The number of mice per group (n) and median survival (ms) are listed. The experiment was performed at least three times.

    Science, 2018, 10(433), doi: 10.1126/scitranslmed.aar1916. Paclitaxel purchased from Selleck.

    Characterization of nuclear damage by PARP as DNA damage repair marker. CLSM images of dual drug conjugated nanoparticle treatments to HeLa cells for 24 h at their respective IC50 drug dosages compared to nontreated control. Cells were stained with PARP-Alexafluor 488 antibody (green).

    ACS Appl Mater Interfaces, 2015, 7(14): 7584-98. Paclitaxel purchased from Selleck.

  • Inhibitory effect of lenvatinib and paclitaxel on the proliferation of ATC cells. Cells were treated with the indicated concentrations of lenvatinib (A) and paclitaxel (B) for 48 h, followed by MTT assay to evaluate cell proliferation. IC50 values of these two drugs for each cell line were calculated using the Reed-Muench method

    Am J Cancer Res, 2017, 7(4):903-912. Paclitaxel purchased from Selleck.

    Western blot analysis of pPRAS40 (T246), pS6 (S240/S244), and pS6 (S235/S236) proteins in (A) HeyA8 cells and (B) SKOV3 cells treated with 0.37 μM or 10 μM paclitaxel in three-dimensional cell culture for 24 hours.

    PLoS One, 2016, 11(5):e0155052. . Paclitaxel purchased from Selleck.

  • Microscope image (406) magnification of U937 cells after exposure to SM-TNs. a) Untreated U937 cells. b) U937 cells treated with 200 nM, and 35 nM ODS empty shells. c) U937 cells treated with microcrystalline (free) Taxol prepared by sonicating Taxol in 20%H3PO4/0.8% SDS solution. d) U937 cells treated with 200 nM SM-TN. A SM-TN is seen in the middle of the picture. e) U937 cells treated with 35 nM SMTN.The nanowires are too small to see at this magnification, but their effect on the cells is clearly visible. Scale bar = 10 mm.

    RSC Adv 2011 1, 884-892. Paclitaxel purchased from Selleck.

产品安全说明书

Microtubule Associated抑制剂选择性比较

生物活性

产品描述 Paclitaxel是一种microtubule聚合物稳定剂,在人内皮细胞中IC50为0.1 pM。
特性 Paclitaxel 是有丝分裂抑制剂。
靶点
Microtubule (human endothelial cells) [1]
0.1 pM
体外研究

Paclitaxel在104到 105倍更高浓度时,抑制非内皮性人类细胞,IC50 为1 nM -10 nM。Paclitaxel选择性抑制细胞增殖,具有种属特异性,在Paclitaxel极低浓度时,小鼠内皮细胞对 Paclitaxel不敏感。 极低浓度Paclitaxel抑制 人类内皮细胞,但是不影响细胞微管结构,且处理的细胞在 G2/M 期没有出现细胞周期停滞和凋亡,说明这是一种新型尚未查明的作用机制。在体外血管生成实验中,在三维纤维蛋白基质中,极低浓度Paclitaxel阻断人类内皮细胞形成芽管。[1] 在SMF存在时, Paclitaxel 作用于 K562 细胞的有效浓度从50 ng/ml降低到 10 ng/ml。在有或无SMF时,Paclitaxel 使K562 细胞周期停滞与DNA损伤相关。[2] Paclitaxel单独处理四种细胞系,包括A549 细胞,H358, H1395 细胞和H1666 细胞,抑制CDK1,这种作用存在时间依赖性。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
TE-15 M{LBTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTBwMECwNlg4KM7:TR?= NVfte5BZW0GQR1XS
LC-2-ad NVLFOXV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjDUXVxUUN3ME2wMlAxODNzNzFOwG0> NULReGlLW0GQR1XS
RL95-2 NF\KcWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fsT2lEPTB;MD6wNFA3PjhizszN NIP0fFRUSU6JRWK=
MZ1-PC M3LyR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\wRWVYUUN3ME2wMlAxODd{OTFOwG0> MX3TRW5ITVJ?
TE-8 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTBwMECxNVch|ryP MXHTRW5ITVJ?
SW954 MorzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrNZXFoUUN3ME2wMlAxOTF7IN88US=> NUPj[mdXW0GQR1XS
TE-11 NGnNPFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvzNWpOUUN3ME2wMlAxOTJ|IN88US=> NHqwUHdUSU6JRWK=
PSN1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3yc4NKSzVyPUCuNFAyOyEQvF2= M1z2fnNCVkeHUh?=
MOLT-4 M{HaPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTXWYFHUUN3ME2wMlAxOTR7IN88US=> MUjTRW5ITVJ?
697 NX75bpY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTBwMECxOUDPxE1? NFzUWG5USU6JRWK=
ETK-1 MnPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTBwMECxOVIh|ryP MorGV2FPT0WU
TE-10 MorxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkW2TWM2OD1yLkCwNVU1KM7:TR?= M4fQSXNCVkeHUh?=
HUTU-80 MnPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTBwMECxOlgh|ryP MkDlV2FPT0WU
NTERA-S-cl-D1 M{TYd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTBwMECyNFkh|ryP NGPWcW5USU6JRWK=
MFH-ino M3r6c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXn0co5oUUN3ME2wMlAxOjZ6IN88US=> M1;SZXNCVkeHUh?=
IA-LM NInVUG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjTTWM2OD1yLkCwNlgh|ryP NU[2NZR5W0GQR1XS
MC116 MofvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17qU2lEPTB;MD6wNFI5QSEQvF2= MV\TRW5ITVJ?
RKO MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrDOIxKSzVyPUCuNFAzQThizszN MV7TRW5ITVJ?
MRK-nu-1 NX7UTm5OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoruTWM2OD1yLkCwNlk6KM7:TR?= M2Lwe3NCVkeHUh?=
VA-ES-BJ MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;jTWM2OD1yLkCwN{DPxE1? NUG5PGdqW0GQR1XS
KALS-1 MkXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\zSFYxUUN3ME2wMlAxOzB6IN88US=> MUPTRW5ITVJ?
BB30-HNC MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\Lfm5KSzVyPUCuNFA{OTRizszN M1fOSXNCVkeHUh?=
ACN NIPpbY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XpeWlEPTB;MD6wNFMyPiEQvF2= NHHmVZlUSU6JRWK=
TE-9 NHHI[3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFG1ZYNKSzVyPUCuNFA{OjZizszN MXrTRW5ITVJ?
SIG-M5 NFnm[olIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWOzfVNOUUN3ME2wMlAxOzJ5IN88US=> NHT2NWVUSU6JRWK=
no-10 MkfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fXfWlEPTB;MD6wNFM3OiEQvF2= MUPTRW5ITVJ?
EW-1 NIrHbo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nMb2lEPTB;MD6wNFM4OSEQvF2= NHS0U5NUSU6JRWK=
SK-LMS-1 NU\vNI5lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULVWFVRUUN3ME2wMlAxPDBzIN88US=> NHHmd3pUSU6JRWK=
GT3TKB NFHCdJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TaW2lEPTB;MD6wNFQ{PCEQvF2= NHX2bldUSU6JRWK=
ES4 NFfadFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUC0W5hWUUN3ME2wMlAxPDR7IN88US=> NX;0e49pW0GQR1XS
IMR-5 NUnWPGhFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjuSI1sUUN3ME2wMlAxPDVizszN NXjhVo9MW0GQR1XS
NCI-H1648 MoG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\sVIE4UUN3ME2wMlAxPDZ7IN88US=> NIPVWmdUSU6JRWK=
MV-4-11 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEm4RlZKSzVyPUCuNFA1PzVizszN NYDu[oZCW0GQR1XS
SK-UT-1 NUnOWlNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXixSotTUUN3ME2wMlAxPDhizszN MYHTRW5ITVJ?
NB13 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPLOnYxUUN3ME2wMlAxPDlzIN88US=> M1L6VXNCVkeHUh?=
DJM-1 NIP4[4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYD2VY5LUUN3ME2wMlAxPTNizszN MlLNV2FPT0WU
ES8 NWDkR5VmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrFeIJKSzVyPUCuNFA2OzhizszN M2LZPHNCVkeHUh?=
TE-6 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDHTWM2OD1yLkCwOVch|ryP NYfDemlVW0GQR1XS
KS-1 M3;IO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXPO|VKSzVyPUCuNFA2QDJizszN MYjTRW5ITVJ?
TE-1 NF;3N2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVy0T|FkUUN3ME2wMlAxPjB4IN88US=> M36wdnNCVkeHUh?=
ATN-1 MmT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPIZWtKSzVyPUCuNFA3ODlizszN M12xRnNCVkeHUh?=
A4-Fuk MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTBwMEC2NVEh|ryP NHH6RWtUSU6JRWK=
ALL-PO NWnxZ5E3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTBwMEC2N{DPxE1? MU\TRW5ITVJ?
BE-13 Ml\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LCN2lEPTB;MD6wNFY{PiEQvF2= NYDGWItLW0GQR1XS
KM12 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFL5fJhKSzVyPUCuNFA3OzdizszN NXXJZYJ7W0GQR1XS
NOS-1 M2r4c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfYbHM5UUN3ME2wMlAxPjVizszN NVrYWmhRW0GQR1XS
SW962 NVf1[nE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTBwMEC2OlIh|ryP M3fqT3NCVkeHUh?=
OCUB-M MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTP[JRKSzVyPUCuNFA3PjJizszN NVHBdVRLW0GQR1XS
NCI-H510A M3vLV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTBwMEC2OlUh|ryP NF7pOoxUSU6JRWK=
EW-16 MojQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTBwMEC2PVQh|ryP NXnqSG5RW0GQR1XS
KGN NWLDbYptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYK5XGNzUUN3ME2wMlAxPzF{IN88US=> MojSV2FPT0WU
LS-411N Mkf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlS1TWM2OD1yLkCwO|E4KM7:TR?= MVHTRW5ITVJ?
Becker MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTBwMEC3NkDPxE1? Mn\MV2FPT0WU
HC-1 NEXuR|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGC1SIFKSzVyPUCuNFA4OjFizszN M{K5cnNCVkeHUh?=
CESS M1rBOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYf6PIRuUUN3ME2wMlAxPzN5IN88US=> NHLCelNUSU6JRWK=
KURAMOCHI M1i5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInuUFVKSzVyPUCuNFA4PDhizszN NWPkPFU2W0GQR1XS
TGBC24TKB M{Tm[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXEW3hKSzVyPUCuNFA4PTJizszN NXvZPFE6W0GQR1XS
SW982 M4TSS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV65OllCUUN3ME2wMlAxPzZ4IN88US=> MVjTRW5ITVJ?
HCE-4 MljzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzuTWM2OD1yLkCwO|Y4KM7:TR?= NWCyNGJLW0GQR1XS
LOUCY M2jjZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTBwMEC3O|Uh|ryP NEfieIVUSU6JRWK=
8-MG-BA NWXDWpR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{H5e2lEPTB;MD6wNFc6PiEQvF2= MWHTRW5ITVJ?
HT-144 MmjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzVTWM2OD1yLkCwPEDPxE1? NUnqSI1RW0GQR1XS
LXF-289 M3n0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\2TZluUUN3ME2wMlAxQDF6IN88US=> M2juNnNCVkeHUh?=
RS4-11 M{\wRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPEO3FWUUN3ME2wMlAxQDN4IN88US=> MmPDV2FPT0WU
DEL NYT3fZNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTBwMEC4OFUh|ryP M3XHVHNCVkeHUh?=
OCI-AML2 MoPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnaeI1KSzVyPUCuNFA5PTJizszN NVnQcHRsW0GQR1XS
CCRF-CEM MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTBwMEC4O|Eh|ryP NW\aVZVJW0GQR1XS
A388 NILBbVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3THe2lEPTB;MD6wNFg4PCEQvF2= M2PmeXNCVkeHUh?=
KNS-42 NE[xU45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLOR3NKSzVyPUCuNFA5QTFizszN MVHTRW5ITVJ?
OVCAR-4 NX[zNlM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTBwMEC5NFQh|ryP MVTTRW5ITVJ?
NCI-H1355 M2jSWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTBwMEC5NVQh|ryP M1nnR3NCVkeHUh?=
BL-70 NVi5UZdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDrTWM2OD1yLkCwPVMh|ryP NHvP[YFUSU6JRWK=
BL-41 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTBwMEC5N|Qh|ryP NHnKXHVUSU6JRWK=
A101D MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLHTWM2OD1yLkCwPVYh|ryP MXfTRW5ITVJ?
HL-60 NFvMfWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfJTWM2OD1yLkCwPVY3KM7:TR?= NFrDPJBUSU6JRWK=
COR-L279 M4HaVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvLV5h2UUN3ME2wMlAxQTl7IN88US=> MoHzV2FPT0WU
NCI-SNU-16 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDPUVNKSzVyPUCuNFExODhizszN M3\lZnNCVkeHUh?=
Calu-6 NFXvbZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTBwMEGwNVIh|ryP NH7lU4pUSU6JRWK=
SR MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlG1TWM2OD1yLkCxNFI3KM7:TR?= MkjyV2FPT0WU
QIMR-WIL M2f6XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLROFFrUUN3ME2wMlAyODN|IN88US=> NXTmZY9IW0GQR1XS
LB647-SCLC NYjicoZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTBwMEGwOVEh|ryP MnW2V2FPT0WU
RPMI-8226 NXrKc5E5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTBwMEGxNFIh|ryP NH60OndUSU6JRWK=
SK-PN-DW NVTk[WI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXUe4ZNUUN3ME2wMlAyOTF{IN88US=> MXnTRW5ITVJ?
SF268 NGTj[oZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LFSGlEPTB;MD6wNVE2OSEQvF2= MVXTRW5ITVJ?
HD-MY-Z MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mof3TWM2OD1yLkCxNVY{KM7:TR?= Mo\QV2FPT0WU
DOHH-2 NH\Wc2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{O3dGlEPTB;MD6wNVIxOyEQvF2= M2[xXHNCVkeHUh?=
SCC-3 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTBwMEGyNFQh|ryP NY\MbodvW0GQR1XS
ST486 NGXIVpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3H5d2lEPTB;MD6wNVIxPCEQvF2= NGXYZo1USU6JRWK=
NALM-6 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWn1[FdjUUN3ME2wMlAyOjF2IN88US=> NH;BU5ZUSU6JRWK=
NCI-H1436 Mn34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXu3WI9yUUN3ME2wMlAyOjNzIN88US=> MWHTRW5ITVJ?
KE-37 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoO5TWM2OD1yLkCxNlM1KM7:TR?= NXPE[oR5W0GQR1XS
RPMI-8402 NUDkRXVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLycZJKSzVyPUCuNFEzPTZizszN M2XK[3NCVkeHUh?=
RXF393 M3HaS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDyTWM2OD1yLkCxNlU4KM7:TR?= MX;TRW5ITVJ?
KARPAS-45 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2X5WmlEPTB;MD6wNVI4KM7:TR?= MmG5V2FPT0WU
HOP-62 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7BTWM2OD1yLkCxNlc3KM7:TR?= MWLTRW5ITVJ?
ES1 NYPYeWdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nrZWlEPTB;MD6wNVI5QCEQvF2= M3HpU3NCVkeHUh?=
L-363 NF21NHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\FV2lEPTB;MD6wNVM2OSEQvF2= Mn64V2FPT0WU
GI-1 NV35eFRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;hTWM2OD1yLkCxN|c{KM7:TR?= NULER5p{W0GQR1XS
CTV-1 NEPhXW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLNSWlKSzVyPUCuNFE1PzhizszN NHLvcGhUSU6JRWK=
TE-5 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LyWmlEPTB;MD6wNVQ6PiEQvF2= NWDWdJB4W0GQR1XS
SNU-C2B MoPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTTW|l4UUN3ME2wMlAyPDl4IN88US=> NUK2WYtIW0GQR1XS
K-562 M3jvVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPhVJJVUUN3ME2wMlAyPTF4IN88US=> MYXTRW5ITVJ?
SNB75 M3Lhbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\GTWM2OD1yLkCxOVQh|ryP MYnTRW5ITVJ?
MOLT-13 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF70TIJKSzVyPUCuNFE3OzdizszN Ml;qV2FPT0WU
LS-123 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTBwMEG2OlQh|ryP MmmxV2FPT0WU
NCI-SNU-5 NF3KUI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTBwMEG3NFEh|ryP NIjzc|NUSU6JRWK=
Daudi M4GyOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmn0TWM2OD1yLkCxO|A5KM7:TR?= NILaTGRUSU6JRWK=
A253 NVXDcVNbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoL0TWM2OD1yLkCxO|M5KM7:TR?= MUDTRW5ITVJ?
TGBC1TKB NVvGV4RQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTBwMEG3OVIh|ryP MnfTV2FPT0WU
SJSA-1 NX3GN3RVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvOb|JKUUN3ME2wMlAyPzZ5IN88US=> M2HXN3NCVkeHUh?=
NCCIT M2nVTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTBwMEG3Olkh|ryP M{\QenNCVkeHUh?=
NCI-H69 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTQZmVuUUN3ME2wMlAyPzd6IN88US=> NF\Cd3ZUSU6JRWK=
SH-4 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTBwMEG4PVUh|ryP MVrTRW5ITVJ?
HCC1187 MojtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7aTGtjUUN3ME2wMlAyQTJ2IN88US=> NIHIUpVUSU6JRWK=
HCC1599 NGfGe5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofITWM2OD1yLkCyNFIh|ryP MXXTRW5ITVJ?
ONS-76 M2K4Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3mRm0{UUN3ME2wMlAzODN4IN88US=> MnjSV2FPT0WU
KU812 NX24UHdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\1Z5h3UUN3ME2wMlAzODN7IN88US=> M3;KcHNCVkeHUh?=
ML-2 NFTZXJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\rNGlEPTB;MD6wNlA1PyEQvF2= MVnTRW5ITVJ?
HCE-T NHfQW|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\pTYFKSzVyPUCuNFIxQTJizszN NH61SVdUSU6JRWK=
NCI-H446 NUjQb4R{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTBwMEKxNVIh|ryP NXLp[FFwW0GQR1XS
RPMI-6666 MoTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnE[mRKSzVyPUCuNFIyPDlizszN M1fUbnNCVkeHUh?=
MOLT-16 NUf6OWpkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7IRYpKSzVyPUCuNFIyPTNizszN NXfyc2NCW0GQR1XS
JiyoyeP-2003 NHLJT2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTBwMEKxO|Yh|ryP M3\zNnNCVkeHUh?=
MHH-PREB-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTBwMEKxPVEh|ryP NHPEZ25USU6JRWK=
MC-CAR NXjIXWdoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjNUIpKSzVyPUCuNFI{OjZizszN NVnLUppyW0GQR1XS
BC-3 MoDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHjOnJEUUN3ME2wMlAzOzR2IN88US=> M3XYOXNCVkeHUh?=
KINGS-1 M{jDNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLJTWM2OD1yLkCyN|U2KM7:TR?= NUK2eIZ[W0GQR1XS
PF-382 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7HTWM2OD1yLkCyN|c5KM7:TR?= MVrTRW5ITVJ?
J-RT3-T3-5 NGTQWZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHITWM2OD1yLkCyN|g{KM7:TR?= MkTWV2FPT0WU
SF539 NFLIfoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTBwMEK0NFEh|ryP NXHmUnRPW0GQR1XS
LB831-BLC NVTFVXpFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rDXGlEPTB;MD6wNlQ5PSEQvF2= MYfTRW5ITVJ?
DMS-114 Mnu0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rqeGlEPTB;MD6wNlUxOiEQvF2= M{n3fnNCVkeHUh?=
LB1047-RCC M2O0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYC5SJZ1UUN3ME2wMlAzPTFizszN MlTPV2FPT0WU
LB771-HNC Mn\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkiwTWM2OD1yLkCyOVM1KM7:TR?= NHP2[G1USU6JRWK=
BB65-RCC M4HLcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlO0TWM2OD1yLkCyOVM1KM7:TR?= Ml\yV2FPT0WU
BV-173 NGLzXZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPTTWM2OD1yLkCyOVU1KM7:TR?= NHmxXZFUSU6JRWK=
ARH-77 NYDZWWFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPyTWM2OD1yLkCyOlAyKM7:TR?= NWnkPJE3W0GQR1XS
IST-MEL1 M3jsN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvCXY5TUUN3ME2wMlAzPjJ|IN88US=> MknTV2FPT0WU
NB1 NFfpRlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlSzTWM2OD1yLkCyOlg4KM7:TR?= NUjIOYp3W0GQR1XS
EoL-1-cell NFX2eItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTBwMEK2PFgh|ryP NFLNd41USU6JRWK=
KY821 Mn6yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7TdFdRUUN3ME2wMlAzPjl5IN88US=> M1HyN3NCVkeHUh?=
CMK MoLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTBwMEK3N|Qh|ryP MmrjV2FPT0WU
NCI-H2126 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTBwMEK3Olgh|ryP M{CxNHNCVkeHUh?=
NCI-H526 NWXocoR2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVi0XJd4UUN3ME2wMlAzQDlzIN88US=> M1fPbnNCVkeHUh?=
COLO-684 MnT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLWRYpIUUN3ME2wMlAzQTB6IN88US=> MXfTRW5ITVJ?
NCI-H747 Ml35S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTBwMEK5N|Mh|ryP M2Pu[nNCVkeHUh?=
JAR MlPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nSOGlEPTB;MD6wNlk1PiEQvF2= M{HONnNCVkeHUh?=
MEG-01 NXf0RlZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvTVnBKSzVyPUCuNFI6PzhizszN MoLjV2FPT0WU
MONO-MAC-6 NWHtfYV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjXTWM2OD1yLkCzNFI{KM7:TR?= Mom1V2FPT0WU
IST-SL1 NX7vSHdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfGNW9KSzVyPUCuNFMxPDJizszN NX7qNnF4W0GQR1XS
CPC-N NGfR[YtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnmWHNKSzVyPUCuNFMxPzlizszN NVm3dWVkW0GQR1XS
NCI-H1963 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3q1[GlEPTB;MD6wN|E{OSEQvF2= NHm1VGJUSU6JRWK=
K052 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELGbGpKSzVyPUCuNFMzPDdizszN NUfMdHRFW0GQR1XS
KM-H2 NETvd2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVf0cGE1UUN3ME2wMlA{OzB5IN88US=> MWjTRW5ITVJ?
TE-12 M{LVeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDweIhbUUN3ME2wMlA{OzB7IN88US=> M2PydnNCVkeHUh?=
TK10 NIDvdVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjXc5BKSzVyPUCuNFM{PTZizszN MlTLV2FPT0WU
NMC-G1 M1m5Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXFVXVKSzVyPUCuNFM1PTJizszN NGfG[JVUSU6JRWK=
no-11 NFG5OmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTBwMEO0O|gh|ryP NVrzUppNW0GQR1XS
NCI-H524 M3zFeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTNTWM2OD1yLkCzOVI6KM7:TR?= M3vmU3NCVkeHUh?=
MHH-CALL-2 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTBwMEO1OlIh|ryP M2Oxc3NCVkeHUh?=
GB-1 NIXZXJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEO1Om1KSzVyPUCuNFM3KM7:TR?= Mn;3V2FPT0WU
OPM-2 NHe3SmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrMe21KSzVyPUCuNFM3PzNizszN NHv1d3lUSU6JRWK=
RH-1 NWLmUJFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vvW2lEPTB;MD6wN|gyQSEQvF2= NUTTV3FUW0GQR1XS
NCI-H64 M{e2TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\5TWM2OD1yLkCzPFU4KM7:TR?= M4rIdXNCVkeHUh?=
EVSA-T NXHGOVBsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTHTWM2OD1yLkCzPVI{KM7:TR?= NXywOJdvW0GQR1XS
KARPAS-299 NHS4dndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTBwMEO5PEDPxE1? MYTTRW5ITVJ?
MZ7-mel NHi5bHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\i[2VKSzVyPUCuNFQxPCEQvF2= Ml7kV2FPT0WU
LB373-MEL-D Mn3xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2H5OGlEPTB;MD6wOFExPSEQvF2= NVHFU5FGW0GQR1XS
HEL NGfEeVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTBwMESxOEDPxE1? NG\GTJBUSU6JRWK=
SW872 NG\2bHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTBwMESyNUDPxE1? NH\WeYhUSU6JRWK=
DU-4475 NYjoWIg3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnX0TWM2OD1yLkC0NlQ1KM7:TR?= MmTIV2FPT0WU
IST-SL2 M2XoOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTBwMESyO|Uh|ryP NH3EdIFUSU6JRWK=
NCI-H82 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\VO3dKSzVyPUCuNFQ{ODdizszN MkO3V2FPT0WU
LC4-1 M1O0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvEfo51UUN3ME2wMlA1OzVzIN88US=> MnyzV2FPT0WU
HDLM-2 NH72UXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrYW4dRUUN3ME2wMlA1Ozl{IN88US=> MULTRW5ITVJ?
MMAC-SF NIXQc25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{O0XmlEPTB;MD6wOFU{PCEQvF2= NGnMe3ZUSU6JRWK=
L-540 NEnqOnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTBwMES2N|kh|ryP MoHuV2FPT0WU
MZ2-MEL NEDZRplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3MTWM2OD1yLkC0O|QzKM7:TR?= MUjTRW5ITVJ?
LU-134-A MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnW1TWM2OD1yLkC0O|c{KM7:TR?= NUXuNogxW0GQR1XS
UACC-257 M2\xRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTBwMES4OFkh|ryP MX3TRW5ITVJ?
NCI-H1581 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vNOGlEPTB;MD6wOFk2OyEQvF2= MoTkV2FPT0WU
NB17 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXB[4xKSzVyPUCuNFQ6PzlizszN MlflV2FPT0WU
SBC-1 NFXjcmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTBwMEWwOFIh|ryP NYfqUZhnW0GQR1XS
TALL-1 NVn1NWV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLVTWM2OD1yLkC1NFQ2KM7:TR?= MVLTRW5ITVJ?
NCI-H1304 NWHGe2lIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fC[mlEPTB;MD6wOVIxQCEQvF2= NUfK[4FDW0GQR1XS
NEC8 M4nibWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13OSmlEPTB;MD6wOVI5PiEQvF2= M3ricHNCVkeHUh?=
CAL-148 MonYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jxfmlEPTB;MD6wOVQ{QSEQvF2= NEj0bmpUSU6JRWK=
CGTH-W-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLpZ|Z[UUN3ME2wMlA2PDR7IN88US=> M2fFPXNCVkeHUh?=
NCI-H889 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrv[WpzUUN3ME2wMlA2PTl{IN88US=> NHzqOlNUSU6JRWK=
GR-ST MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYW5W4szUUN3ME2wMlA2PjJzIN88US=> NVTyOItSW0GQR1XS
KARPAS-422 NF\oRXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7FTWM2OD1yLkC1OlUh|ryP MlLyV2FPT0WU
RPMI-8866 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnVSI0xUUN3ME2wMlA2PzF{IN88US=> MUTTRW5ITVJ?
SCLC-21H NX;Pc5BUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DRO2lEPTB;MD6wOVg5PCEQvF2= MVnTRW5ITVJ?
COR-L88 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEK5eYRKSzVyPUCuNFU6OjdizszN NWW1emdbW0GQR1XS
LU-139 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWiw[JlwUUN3ME2wMlA2QTh4IN88US=> M1;UOnNCVkeHUh?=
SF126 M1zJ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfXcJViUUN3ME2wMlA3OTN|IN88US=> M{[zUHNCVkeHUh?=
NCI-H1882 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmP2TWM2OD1yLkC2OFI1KM7:TR?= MkDEV2FPT0WU
EW-24 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPuTWM2OD1yLkC2OFg{KM7:TR?= NEm1b|FUSU6JRWK=
CP67-MEL M3PwdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XldmlEPTB;MD6wOlgyKM7:TR?= MkXMV2FPT0WU
DG-75 MmLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\TPHhKSzVyPUCuNFY5QTlizszN MnmzV2FPT0WU
LOXIMVI NFXl[IFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLPbmVTUUN3ME2wMlA4ODJ6IN88US=> M2KzfXNCVkeHUh?=
HH NHi1XmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PEN2lEPTB;MD6wO|E2PyEQvF2= M1q3U3NCVkeHUh?=
K5 NGjWeG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHMTWM2OD1yLkC3NlI3KM7:TR?= NWr0SHV7W0GQR1XS
EC-GI-10 M2fkT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fBWmlEPTB;MD6wO|I2PyEQvF2= MXnTRW5ITVJ?
SK-N-DZ MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTBwMEezNFch|ryP NYS5OG1HW0GQR1XS
A3-KAW MmX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTSc3pwUUN3ME2wMlA4OzVzIN88US=> M3PhZXNCVkeHUh?=
MLMA MnrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYT6fGpYUUN3ME2wMlA4PDZ3IN88US=> M1vVOXNCVkeHUh?=
LB996-RCC MnvHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHP4OHhKSzVyPUCuNFc4ODdizszN MYLTRW5ITVJ?
OS-RC-2 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml6yTWM2OD1yLkC3O|Q5KM7:TR?= Mo\kV2FPT0WU
CTB-1 Mn;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzPTWM2OD1yLkC3PFEh|ryP MmTWV2FPT0WU
IST-MES1 M3XDUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4exT2lEPTB;MD6wO|kyOiEQvF2= M{\wN3NCVkeHUh?=
LS-1034 NWD4NWJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPQfIpDUUN3ME2wMlA5ODN3IN88US=> Mo\sV2FPT0WU
HT M{LW[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTBwMEiwPFYh|ryP MlrrV2FPT0WU
NCI-H2141 M4XR[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInVbGFKSzVyPUCuNFgyKM7:TR?= MXvTRW5ITVJ?
LB2518-MEL MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTBwMEixOFEh|ryP MVzTRW5ITVJ?
GI-ME-N NHTHbVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmr3TWM2OD1yLkC4OFUzKM7:TR?= NHizRXBUSU6JRWK=
TGW M{fIc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jaVWlEPTB;MD6wPFYxPyEQvF2= MVHTRW5ITVJ?
SK-NEP-1 M1PJT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;CTWM2OD1yLkC4OlQyKM7:TR?= M33qXnNCVkeHUh?=
NOMO-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTz[IRWUUN3ME2wMlA6Ojd3IN88US=> MmXSV2FPT0WU
ES6 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTBwMEm1PFkh|ryP MXrTRW5ITVJ?
NCI-H209 M4rTfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGr4UIRKSzVyPUCuNFk4QDZizszN NWO0O|E1W0GQR1XS
GAK NELJbXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1Poc2lEPTB;MD6xNFE3KM7:TR?= MmPiV2FPT0WU
BC-1 M1rONmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfDTWM2OD1yLkGwN|YyKM7:TR?= NV61eJBIW0GQR1XS
KLE M4frW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTJTWM2OD1yLkGwOFQ{KM7:TR?= NFS0bpZUSU6JRWK=
EW-3 NYLUU5ZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjIVJI4UUN3ME2wMlExQThizszN M3vRXnNCVkeHUh?=
NKM-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3DNYhpUUN3ME2wMlEyOSEQvF2= NGHBV5hUSU6JRWK=
D-336MG MnyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mle1TWM2OD1yLkGxNlQ1KM7:TR?= NGr4XVJUSU6JRWK=
NB69 NXHXcZNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDHVXlKSzVyPUCuNVE{ODFizszN M4PjTXNCVkeHUh?=
D-263MG MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUP5PWFUUUN3ME2wMlEyPzF{IN88US=> MYnTRW5ITVJ?
KP-N-YS M1fscGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPJTWM2OD1yLkGyNlkyKM7:TR?= MX3TRW5ITVJ?
NCI-H1155 NWjRWldwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXsWGd2UUN3ME2wMlEzPTV6IN88US=> MYDTRW5ITVJ?
BOKU M2fod2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NESx[lJKSzVyPUCuNVI2PzlizszN NWrCfnhOW0GQR1XS
LAMA-84 M{OzPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2Hi[2lEPTB;MD6xNlk6KM7:TR?= MnnrV2FPT0WU
Raji NEDwfo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\nSJN7UUN3ME2wMlE{OTF5IN88US=> NILrdZVUSU6JRWK=
LU-65 Ml7nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnj6TWM2OD1yLkGzN|A4KM7:TR?= NIr6NoZUSU6JRWK=
NCI-H187 MnLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTBwMUO5NlQh|ryP MkXqV2FPT0WU
GCIY NUnFc|RiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\NeGhKSzVyPUCuNVQ6ODFizszN MnLOV2FPT0WU
NCI-H2107 MkjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTRb|lqUUN3ME2wMlE2ODhizszN NGrXeVVUSU6JRWK=
NCI-H1522 M{OwZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXjTWM2OD1yLkG1NlY3KM7:TR?= NInyUopUSU6JRWK=
NB6 M4XVSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fodWlEPTB;MD6xOVYzOyEQvF2= MYrTRW5ITVJ?
EM-2 Mnz0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmL2TWM2OD1yLkG1O|A3KM7:TR?= MUjTRW5ITVJ?
HCC2218 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTBwMUW5PEDPxE1? M1q5VXNCVkeHUh?=
NCI-H748 M3fiUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF:2O3dKSzVyPUCuNVY{PzZizszN MUjTRW5ITVJ?
MS-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfNZ2lKSzVyPUCuNVY2OzdizszN MVnTRW5ITVJ?
NB5 NHrCV2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTBwMU[1PVch|ryP MljyV2FPT0WU
OMC-1 NIjkRmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDXTWM2OD1yLkG2Olg5KM7:TR?= MVjTRW5ITVJ?
NCI-H345 M2rlUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTBwMU[5Nlgh|ryP MoDiV2FPT0WU
L-428 NE\ET5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTiTWM2OD1yLkG2PVQ2KM7:TR?= MlzlV2FPT0WU
SCH NH61[4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;SU2hwUUN3ME2wMlE5Pjh3IN88US=> NEHxXHBUSU6JRWK=
NCI-H1417 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTBwMUmyNlch|ryP NIjOfnlUSU6JRWK=
COLO-320-HSR MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jXRmlEPTB;MD6xPVU{OiEQvF2= NX3MO2R[W0GQR1XS
BT-474 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLOTWM2OD1yLkKwPFkzKM7:TR?= NEjBN4pUSU6JRWK=
GDM-1 Mke4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTBwMkG5O|Eh|ryP MonJV2FPT0WU
NCI-H2196 NWrZTXpOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofDTWM2OD1yLkKyNlM2KM7:TR?= MX\TRW5ITVJ?
KP-N-RT-BM-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rvd2lEPTB;MD6yNlM1QSEQvF2= MV7TRW5ITVJ?
KNS-81-FD NUPCPZdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnSxTWM2OD1yLkKyPVU5KM7:TR?= M1zYRXNCVkeHUh?=
COLO-668 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfk[nZKSzVyPUCuNlM3PzVizszN Mn7uV2FPT0WU
C2BBe1 MkS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXm0V5ZPUUN3ME2wMlI3PzR5IN88US=> NUfrcXBIW0GQR1XS
Ramos-2G6-4C10 MoLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnPdpBmUUN3ME2wMlI3QTV2IN88US=> M1PEOXNCVkeHUh?=
CAS-1 NYq5cnNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrCWHFVUUN3ME2wMlI4ODl4IN88US=> MYfTRW5ITVJ?
GOTO M13sbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LsWWlEPTB;MD6yO|g6PCEQvF2= MWTTRW5ITVJ?
LP-1 NYnKenJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTBwMkiwOVch|ryP M1[xXnNCVkeHUh?=
NCI-SNU-1 NYTYToJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\zNWlEPTB;MD6yPVQzOiEQvF2= NWjiPIRHW0GQR1XS
EB-3 MonGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXPTWM2OD1yLkK5PVc6KM7:TR?= NVv6V2FsW0GQR1XS
MHH-NB-11 M2PQOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEG1OI1KSzVyPUCuN|A1ODJizszN M1fI[3NCVkeHUh?=
SK-N-FI NXHjeIxxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\zeZZtUUN3ME2wMlMyPjl{IN88US=> M3PkenNCVkeHUh?=
HCC2157 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nqe2lEPTB;MD6zN|kyOyEQvF2= NV;6SGxHW0GQR1XS
SIMA NW\SN5FqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3X4NGlEPTB;MD6zOFU5OSEQvF2= NHnW[W1USU6JRWK=
MDA-MB-134-VI MljyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTBwM{[5Nlgh|ryP NU\RVJVHW0GQR1XS
NCI-H1694 NXr5PFRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG[zWZBKSzVyPUCuN|ch|ryP MX3TRW5ITVJ?
EHEB NXG5VlZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPNV5RKSzVyPUCuN|kxQDVizszN NEG4U2tUSU6JRWK=
U-266 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTBwM{m4OFYh|ryP MXfTRW5ITVJ?
LC-1F NFfFOVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnCWVZKSzVyPUCuOFM4PjVizszN M2\QZXNCVkeHUh?=
SHP-77 MnXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzwTWM2OD1yLkS3PFU2KM7:TR?= NE\pXXVUSU6JRWK=
LS-513 MlzwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHHTWM2OD1yLkS5N|A4KM7:TR?= NGG4[GxUSU6JRWK=

... Click to View More Cell Line Experimental Data

体内研究 Paclitaxel单独处理 BC-V 和 BC-ER肿瘤的抑制定额分别为49.78 和 51.23%。20 mg/kg Paclitaxel处理6个周期,显著降低Ki-67阳性细胞百分比,BC-V肿瘤中降到20.4%,BC-ER 肿瘤中降到25.1%。[5]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:

[1]

+ 展开
  • Cell lines: 细胞,包括人类新生儿皮肤微血管内皮细胞(HMVECs), 人脐静脉内皮细胞(HUVECs), 人脐动脉内皮细胞 (HUAVECs), 正常人类星形胶质细胞(NHAs), 正常人体皮肤成纤维细胞(NHDFs), 正常人表皮角质形成细胞(NHEKs), 人类乳腺上皮细胞(HMEpCs), 人前列腺上皮细胞(PrEpCs) 和人脐动脉平滑肌细胞(UASMCs)
  • Concentrations: 0.1 pM-100 pM
  • Incubation Time: 72 小时
  • Method:

    培养细胞,包括人类新生儿皮肤微血管内皮细胞(HMVECs), 人脐静脉内皮细胞(HUVECs), 人脐动脉内皮细胞 (HUAVECs), 正常人类星形胶质细胞(NHAs), 正常人体皮肤成纤维细胞(NHDFs), 正常人表皮角质形成细胞(NHEKs), 人类乳腺上皮细胞(HMEpCs), 人前列腺上皮细胞(PrEpCs) 和人脐动脉平滑肌细胞(UASMCs)。在96孔板中使用6和12通道的细胞进行增殖。细胞按每孔3000–5000个细胞接种,然后粘附4小时。Paclitaxel在培养基中稀释,然后按一式四份加到孔中,细胞温育3天,然后加入MTS 试剂,然后定量测量每孔中的活细胞。


    (Only for Reference)
动物实验:

[5]

+ 展开
  • Animal Models: 携带BC-V 和 BC-ER肿瘤的雌性20-22 g 纯和裸鼠
  • Formulation: Dissolved in absolute ethanol with an equal volume of cremophor and diluted 1:4 with sterile physiological saline before use.
  • Dosages: 20 mg/kg
  • Administration: 静脉注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 171 mg/mL (200.25 mM)
Ethanol 18 mg/mL (21.07 mM)
Water Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+5% Tween 80+ddH2O
2.5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 853.91
化学式

C47H51NO14

CAS号 33069-62-4
稳定性 powder
in solvent
别名 NSC 125973

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03400306 Not yet recruiting Cancer - Ovarian AbbVie May 10 2020 Phase 1
NCT03704077 Not yet recruiting Gastric Cancer|Cancer of the Stomach|Stomach Cancer|Gastroesophageal Junction Bristol-Myers Squibb May 15 2019 Phase 2
NCT03199885 Not yet recruiting Breast Adenocarcinoma|HER2/Neu Positive|Recurrent Breast Carcinoma|Stage III Breast Cancer AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7 National Cancer Institute (NCI) May 10 2019 Phase 3
NCT03742986 Not yet recruiting Breast Cancer New York University School of Medicine April 2019 Phase 2
NCT03417921 Not yet recruiting Pancreatic Cancer Ability Pharmaceuticals SL|The Cleveland Clinic April 1 2019 Phase 1|Phase 2
NCT03725436 Not yet recruiting Advanced Malignant Solid Neoplasm|Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IIIA Breast Cancer AJCC v8|Anatomic Stage IIIB Breast Cancer AJCC v8|Anatomic Stage IIIC Breast Cancer AJCC v8|Estrogen Receptor Positive|HER2/Neu Negative|Metastatic Malignant Solid Neoplasm|Prognostic Stage III Breast Cancer AJCC v8|Prognostic Stage IIIA Breast Cancer AJCC v8|Prognostic Stage IIIB Breast Cancer AJCC v8|Prognostic Stage IIIC Breast Cancer AJCC v8|Recurrent Breast Carcinoma|TP53 wt Allele|Unresectable Malignant Solid Neoplasm M.D. Anderson Cancer Center|National Cancer Institute (NCI) March 31 2019 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    I am interested in the product S1150 for in vivo studies, could you please give some suggestions for the formulation?

  • 回答:

    S1150 in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 30mg/ml is a suspension. If the you want to inject it, there is another vehicle, 5% DMSO+5% Tween 80+ddH2O. S1150 can dissolve in it at 2.5mg/ml as a clear solution. It is a common formulation we used, but is not cited from reference.

  • 问题 2:

    the compound was dissolved into 1ml DMSO and diluted with 1x PBS or water (500ul + 9.5 ml PBS or water). I found the white precipitation goes out. How to figure it out?

  • 回答:

    Paclitaxel has very low solubility in water based solution and that's why it precipitated out once you dilute the stock with water. The vehicle we suggest is: 1% DMSO+30% polyethylene glycol+1% Tween 80.

Microtubule Associated Signaling Pathway Map

相关Microtubule Associated产品

Tags: 购买Paclitaxel | Paclitaxel供应商 | 采购Paclitaxel | Paclitaxel价格 | Paclitaxel生产 | 订购Paclitaxel | Paclitaxel代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID